TrialThe Lancet. Oncology2013

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.

Tom Waddell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.